

**HB 1435 – Health Insurance Coverage for Hormone-Related Care**  
**Position: Favorable**

Chair, Vice Chair, and Members of the Committee,

My name is **Abbe Berman**, and I serve as **Vice President of Women’s Health Initiatives at Big Tree Innovation Fund**, where I focus on advancing innovation, investment, and policy solutions that improve care for women across the lifespan.

I respectfully submit this testimony in **support of HB 1435**, which addresses access to hormone-related care.

Hormonal health is a fundamental component of women’s health, affecting millions of women across their lives. Nearly **1.3 million women in the United States enter menopause each year**, and women now spend **approximately one-third of their lives in post-menopause**. Hormone-related conditions—including perimenopause, menopause, and other endocrine-related health issues—can significantly affect cardiovascular health, bone health, cognitive function, and overall quality of life.

Despite the prevalence of these conditions, access to evidence-based hormone-related care remains inconsistent. Many women encounter barriers due to gaps in insurance coverage, limited clinician training, and fragmented care pathways. As a result, patients often struggle to obtain medically appropriate treatment for symptoms that can significantly impact daily functioning, workplace participation, and long-term health outcomes.

In my work advancing women’s health innovation and engaging in policy discussions related to menopause and midlife care, I have seen growing recognition that improving access to hormone-related care is both a healthcare priority and an opportunity to modernize how our healthcare system addresses women’s health across the lifespan.

States that strengthen women’s health policy are also creating the conditions for innovation. Across the healthcare sector, we are seeing rapid growth in new care models, diagnostics, digital health platforms, and therapeutic approaches focused on women’s health and midlife care. Ensuring that patients can access treatment through insurance coverage is essential to supporting both improved patient outcomes and the continued advancement of women’s health innovation.

HB 1435 represents an important step toward addressing longstanding gaps in women’s healthcare and ensuring that patients can access medically appropriate hormone-related care.

For these reasons, I respectfully urge the Committee to issue a **favorable report on HB 1435**.

Thank you for your consideration.

Abbe Berman  
Vice President, Women’s Health Initiatives  
Big Tree Innovation Fund

